JP2021532829A5 - - Google Patents
Info
- Publication number
- JP2021532829A5 JP2021532829A5 JP2021528490A JP2021528490A JP2021532829A5 JP 2021532829 A5 JP2021532829 A5 JP 2021532829A5 JP 2021528490 A JP2021528490 A JP 2021528490A JP 2021528490 A JP2021528490 A JP 2021528490A JP 2021532829 A5 JP2021532829 A5 JP 2021532829A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antibody
- cell population
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024170336A JP2025011150A (ja) | 2018-07-26 | 2024-09-30 | ガンマ－デルタｔ細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862703654P | 2018-07-26 | 2018-07-26 | |
| US62/703,654 | 2018-07-26 | ||
| PCT/EP2019/070125 WO2020021045A2 (en) | 2018-07-26 | 2019-07-25 | Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024170336A Division JP2025011150A (ja) | 2018-07-26 | 2024-09-30 | ガンマ－デルタｔ細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532829A JP2021532829A (ja) | 2021-12-02 |
| JP2021532829A5 true JP2021532829A5 (enExample) | 2022-08-15 |
| JP7565271B2 JP7565271B2 (ja) | 2024-10-10 |
Family
ID=67847672
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021528490A Active JP7565271B2 (ja) | 2018-07-26 | 2019-07-25 | ガンマ－デルタｔ細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法 |
| JP2024170336A Pending JP2025011150A (ja) | 2018-07-26 | 2024-09-30 | ガンマ－デルタｔ細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024170336A Pending JP2025011150A (ja) | 2018-07-26 | 2024-09-30 | ガンマ－デルタｔ細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200032211A1 (enExample) |
| EP (1) | EP3827074A2 (enExample) |
| JP (2) | JP7565271B2 (enExample) |
| KR (1) | KR102883631B1 (enExample) |
| CN (1) | CN112912494B (enExample) |
| AU (1) | AU2019311290B2 (enExample) |
| CA (1) | CA3106056A1 (enExample) |
| SG (1) | SG11202100320QA (enExample) |
| WO (1) | WO2020021045A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11293021B1 (en) | 2016-06-23 | 2022-04-05 | Inscripta, Inc. | Automated cell processing methods, modules, instruments, and systems |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| JP2020530979A (ja) | 2017-06-30 | 2020-11-05 | インスクリプタ， インコーポレイテッド | 自動細胞処理方法、モジュール、機器及びシステム |
| US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
| US10557216B2 (en) | 2018-04-24 | 2020-02-11 | Inscripta, Inc. | Automated instrumentation for production of T-cell receptor peptide libraries |
| CA3108767A1 (en) | 2018-06-30 | 2020-01-02 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
| US11142740B2 (en) | 2018-08-14 | 2021-10-12 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
| US11214781B2 (en) | 2018-10-22 | 2022-01-04 | Inscripta, Inc. | Engineered enzyme |
| CN109517793B (zh) * | 2018-11-30 | 2022-05-10 | 广州长峰生物技术有限公司 | 一种NK细胞和γδT细胞共培养的建立方法 |
| US11001831B2 (en) | 2019-03-25 | 2021-05-11 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
| AU2020247900A1 (en) | 2019-03-25 | 2021-11-04 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
| AU2020288623A1 (en) | 2019-06-06 | 2022-01-06 | Inscripta, Inc. | Curing for recursive nucleic acid-guided cell editing |
| US11203762B2 (en) | 2019-11-19 | 2021-12-21 | Inscripta, Inc. | Methods for increasing observed editing in bacteria |
| AU2020407048A1 (en) | 2019-12-18 | 2022-06-09 | Inscripta, Inc. | Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells |
| GB202000934D0 (en) * | 2020-01-22 | 2020-03-04 | Ucl Business Ltd | Engineered immune cells |
| US11225674B2 (en) | 2020-01-27 | 2022-01-18 | Inscripta, Inc. | Electroporation modules and instrumentation |
| US20210238535A1 (en) * | 2020-02-02 | 2021-08-05 | Inscripta, Inc. | Automated production of car-expressing cells |
| WO2021221766A2 (en) * | 2020-02-19 | 2021-11-04 | Barron Annelise E | A method of treating cancer by upregulating cathelicidin gene expression and infusing natural killer cells |
| CA3168378A1 (en) * | 2020-02-28 | 2021-09-02 | Avm Biotechnology, Llc | Lypmphocyte population and methods for producing same |
| US20210332388A1 (en) | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
| US11787841B2 (en) | 2020-05-19 | 2023-10-17 | Inscripta, Inc. | Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli |
| AU2021298707A1 (en) * | 2020-06-30 | 2023-02-23 | Nanjing IASO Biotechnology Co., Ltd. | Fully humanized bispecific chimeric antigen receptor targeting CD19 and CD22 and use thereof |
| GB202013962D0 (en) * | 2020-09-04 | 2020-10-21 | Gammadelta Therapeutics Ltd | Immunotherapy composition |
| US11299731B1 (en) | 2020-09-15 | 2022-04-12 | Inscripta, Inc. | CRISPR editing to embed nucleic acid landing pads into genomes of live cells |
| CN112300992B (zh) * | 2020-10-27 | 2023-05-23 | 杜德(江门)生物科技有限公司 | 一种nk细胞培养液及多级激活nk细胞的培养方法 |
| US11512297B2 (en) | 2020-11-09 | 2022-11-29 | Inscripta, Inc. | Affinity tag for recombination protein recruitment |
| WO2022109477A1 (en) * | 2020-11-23 | 2022-05-27 | University Of Florida Research Foundation, Incorporated | Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes |
| IT202000030266A1 (it) * | 2020-12-10 | 2022-06-10 | Ospedale Pediatrico Bambino Gesù | Car t cells for treating cd19+, cd20+ or cd22+ tumors. |
| CN112501127B (zh) * | 2020-12-21 | 2023-10-10 | 广东昭泰细胞生物科技有限公司 | 一种重编程nk细胞的培养方法 |
| AU2021415461A1 (en) | 2021-01-04 | 2023-08-17 | Inscripta, Inc. | Mad nucleases |
| EP4274890A4 (en) | 2021-01-07 | 2024-11-27 | Inscripta, Inc. | MAD-NUCLEASES |
| US11884924B2 (en) | 2021-02-16 | 2024-01-30 | Inscripta, Inc. | Dual strand nucleic acid-guided nickase editing |
| GB202105113D0 (en) * | 2021-04-09 | 2021-05-26 | Gammadelta Therapeutics Ltd | Novel method |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| CN113667640B (zh) * | 2021-08-27 | 2022-09-02 | 广州百暨基因科技有限公司 | CAR-γδT细胞的制备方法 |
| GB202115389D0 (en) * | 2021-10-26 | 2021-12-08 | XNK Therapeutics AB | Methods |
| EP4183871A1 (en) * | 2021-11-23 | 2023-05-24 | Université d'Aix-Marseille | Process for preparing a composition comprising a combined cell population |
| CN114107200B (zh) * | 2021-11-29 | 2023-04-21 | 华东师范大学 | 一种高纯度CD56+γδT细胞及其制备方法和用途 |
| GB202204926D0 (en) * | 2022-04-04 | 2022-05-18 | Gammadelta Therapeutics Ltd | Method for expanding gammadelta T cells |
| IL320156A (en) * | 2022-10-10 | 2025-06-01 | Kite Pharma Inc | New large scale car-t immune cell manufacturing method utilizing lentiviral vector transfection |
| CN115651903B (zh) * | 2022-11-14 | 2023-03-17 | 四川新生命干细胞科技股份有限公司 | 高杀伤力的免疫细胞群及其培养方法、试剂组合物和应用 |
| WO2024129862A2 (en) * | 2022-12-13 | 2024-06-20 | Dana-Farber Cancer Institute, Inc. | Checkpoint modulators for enhancing immunotherapy |
| KR20250172550A (ko) * | 2023-01-17 | 2025-12-09 | 안선 바이오파르마, 아이엔씨. | 감마 델타 t 세포의 생성 방법 |
| WO2025046256A1 (en) * | 2023-08-31 | 2025-03-06 | Universite D'aix-Marseille | Process for preparing a composition comprising a combined cell population |
| WO2025262647A1 (en) | 2024-06-20 | 2025-12-26 | Istituto Giannina Gaslini | Product for advanced cell therapy |
| ES3034332A1 (es) * | 2025-05-21 | 2025-08-14 | Univ Madrid Complutense | Método de expansión selectiva in vitro y adquisición de fenotipo residente en tejido decélulas T Yo Vo1+ derivadas de sangre periférica |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1317108B1 (it) | 2000-12-06 | 2003-05-26 | Philogen Srl | Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso. |
| JP2010220479A (ja) | 2007-06-15 | 2010-10-07 | Medeinetto:Kk | Ｎｋ細胞の培養方法及びｎｋ細胞の利用 |
| PT2710123T (pt) * | 2011-05-19 | 2017-10-13 | Inst De Medicina Molecular | Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos |
| RU2021118125A (ru) * | 2014-12-29 | 2022-04-06 | Новартис Аг | Способы получения экспрессирующих химерный антигенный рецептор клеток |
| CA2992551A1 (en) * | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| US11299708B2 (en) * | 2016-05-12 | 2022-04-12 | Adicet Bio, Inc. | Methods for selective expansion of γδ T-cell populations and compositions thereof |
-
2019
- 2019-07-25 CA CA3106056A patent/CA3106056A1/en active Pending
- 2019-07-25 WO PCT/EP2019/070125 patent/WO2020021045A2/en not_active Ceased
- 2019-07-25 JP JP2021528490A patent/JP7565271B2/ja active Active
- 2019-07-25 KR KR1020217006025A patent/KR102883631B1/ko active Active
- 2019-07-25 CN CN201980062358.8A patent/CN112912494B/zh active Active
- 2019-07-25 AU AU2019311290A patent/AU2019311290B2/en active Active
- 2019-07-25 EP EP19762715.1A patent/EP3827074A2/en active Pending
- 2019-07-25 SG SG11202100320QA patent/SG11202100320QA/en unknown
- 2019-08-30 US US16/557,316 patent/US20200032211A1/en not_active Abandoned
-
2021
- 2021-08-06 US US17/396,487 patent/US20210380944A1/en active Pending
-
2024
- 2024-09-30 JP JP2024170336A patent/JP2025011150A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532829A5 (enExample) | ||
| JP7604366B2 (ja) | 遺伝子操作されたｔ細胞を作製するための方法 | |
| JP6998763B2 (ja) | Ｔ細胞またはｎｋ細胞を活性化および増加させるための、可溶性抗体複合体 | |
| ES2240962T3 (es) | Metodo para estimular selectivamente la proliferacion de celulas t. | |
| JP2021530236A5 (enExample) | ||
| JP5607357B2 (ja) | 抗原特異的ｂ細胞のクローン集団を獲得するための培養方法 | |
| ES2569240T3 (es) | Polipéptidos y anticuerpos obtenidos a partir de células de leucemia linfocítica crónica y usos de los mismos | |
| JP2020202867A (ja) | キメラ受容体及びその使用方法 | |
| BR112021002390A2 (pt) | processos para gerar células modificadas e suas composições | |
| Playoust et al. | Germinal center-dependent and-independent immune responses of tumor-infiltrating B cells in human cancers | |
| JP2018008949A (ja) | 新規モジュレーターと使用の方法 | |
| EP1819830A2 (en) | Methods for antibody engineering | |
| JP2022505445A5 (enExample) | ||
| JP2021513337A5 (enExample) | ||
| JP2024507540A5 (enExample) | ||
| JP2014518080A (ja) | 細胞のスクリーニング方法 | |
| CN107428827A (zh) | 通过b细胞淘选和增殖高通量产生单克隆抗体 | |
| Hohlfeld et al. | Reflections on the “intrathymic pathogenesis” of myasthenia gravis | |
| JP2023169422A (ja) | 結合ポリペプチドおよびそれを作製する方法 | |
| KR20200098518A (ko) | δ3 γδ T-세포 집단의 선택적 증식을 위한 방법 및 이의 조성물 | |
| JP2020530766A (ja) | フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法 | |
| US20210290672A1 (en) | Regulation of tumor-associated t cells | |
| JP2022510387A5 (enExample) | ||
| EP2491399A1 (en) | Prognostic, screening and treatment methods and agents for treatment of metastasis and inflammation using t54 oncofoetal glycoprotein | |
| JP2009507835A5 (enExample) |